Brief: Iovance’s Amtagvi Receives Health Canada Approval for Advanced Melanoma
18/08/2025 21:18
Aug 18 (Reuters) - Iovance Biotherapeutics Inc IOVA.O: IOVANCE’S AMTAGVI® (LIFILEUCEL) RECEIVES HEALTH CANADA APPROVAL FOR ADVANCED MELANOMA Source text: ID:nGNXbtpXpR Further company coverage: IOVA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Iovance Biotherapeutics
See all newsBrief: Iovance Biotherapeutics Reports Inducement Grants
US RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Brief: Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., As Chief Medical Officer
Iovance hits two-year high after raising annual revenue forecast
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies